Ascendis Pharmaの空売り状況は、投資家がAscendis Pharmaの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Ascendis Pharma (NASDAQ:ASND) 株価情報, 空売り情報

Ascendis Pharma

Ascendis Pharma AS is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma AS

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) has outperformed the market over the past 10 years by 37.07% on an annualized basis producing an average annual return of 48.79%. Currently, Ascendis Pharma has a market capitalization of $7.46 billion. 
Buying $100 In ASND: If an investor had bought $100 of ASND stock 10 years ago, it would be worth $5,187.24 today based on a price of $124.81 for ASND at the time of writing.
<h3>Ascendis Pharma's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737642609_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

ASND

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years

Ascendis Pharma's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NYSE">ASND</a>) short percent of float has fallen 5.74% since its last report. The company recently reported that it has 3.42 million shares sold short, which is 8.04% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.76 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ascendis Pharma Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736955011_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ascendis Pharma has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Ascendis Pharma's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ascendis Pharma's peer group average for short interest as a percentage of float is 11.50%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Ascendis Pharma's Recent Short Interest

Financial Update
<ul>
<li>Unaudited preliminary estimate of total full-year 2024 product revenue of ~€226 million:
<ul>
<li>SKYTROFA full-year 2024 revenue expected to be ~€202 million excluding sales deductions related to prior years (based on unaudited preliminary estimate of full-year 2024 SKYTROFA revenue of ~€197 million plus ~€5 million of sales deductions related to prior years).</li>
<li>YORVIPATH full-year 2024 unaudited preliminary revenue estimate of ~€29 million.</li>
</ul>
</li>
<li>Unaudited preliminary estimate of total full-year total 2024 revenue of ~€364 million
<ul>
<li>Includes $100 million Novo Nordisk milestone payment as non-product revenue.</li>
</ul>
</li>
<li>December 31, 2024 pro forma cash balance of ~€655 million (based on unaudited preliminary estimate of December 31, 2024 cash balance of €560 million plus expected payment from Novo Nordisk of $100 million).</li>
</ul>

Reported Earlier, Ascendis Pharma Projects €364M In 2024 Revenue, Reports €655M In Cash, Highlights SKYTROFA And YORVIPATH Growth, And Prepares For Transcon CNP NDA Filing In Early 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler analyst Mike Lavery initiated coverage on The Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) with an Overweight rating and announced a price target of $74. Coca-Cola shares closed at $60.81 on Monday. <a href="https://www.benzinga.com/quote/KO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities analyst John McDonald initiated coverage on JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) with a Hold rating and announced a price target of $260. JPMorgan shares closed at $240.85 on Monday. <a href="https://www.benzinga.com/quote/JPM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital analyst Sean Dodge initiated coverage on ICON Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with an Outperform rating and announced a price target of $263. Icon shares closed at $215.51 on Monday. <a href="https://www.benzinga.com/quote/ICLR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Eliana Merle initiated coverage on Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Buy rating and announced a price target of $196. Ascendis Pharma shares closed at $140.28 on Monday. <a href="https://www.benzinga.com/quote/ASND/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald analyst Ross Osborn initiated coverage on Anteris Technologies Global Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVR#NASDAQ">AVR</a>) with an Overweight rating and announced a price target of $9. Anteris Technologies shares closed at $5.61 on Monday. <a href="https://www.benzinga.com/quote/AVR/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying KO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07090849/image-35-1024x486.png" alt="" class="wp-image-721909" style="width:491px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07090849/image-35-1024x486.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07090849/image-35-300x142.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07090849/image-35-768x364.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07090849/image-35.png 1142w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42839544/wells-fargo-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Wells Fargo Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

ICLR

This Coca-Cola Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

UBS analyst Eliana Merle initiates coverage on Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Buy rating and announces Price Target of $196.

Price Target

UBS Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $196

Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) today announced that YORVIPATH&#xAE; (palopegteriparatide; developed as TransCon PTH) is now commercially available by prescription in the United States. YORVIPATH is a prodrug of parathyroid hormone (PTH [1-34]), administered once-daily, designed to provide continuous exposure to active PTH over the 24-hour dosing period. It is the first and only medicine approved by the U.S. Food &amp; Drug Administration (FDA) for the treatment of hypoparathyroidism in adults.

Biotech

General

Ascendis Pharma's YORVIPATH Now Commercially Available In The U.S. For The Treatment Of Hypoparathyroidism In Adults

- Results for all three TransCon hGH starting dose cohorts, in first clinical trial of an indication outside of growth hormone deficiency, showed a safety and tolerability profile comparable to daily somatropin
- Annualized height velocity was similar at Week 26 in once-weekly TransCon hGH-treated and daily somatropin-treated children
COPENHAGEN, Denmark, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) today announced positive Week 26 topline results from New InsiGHTS, its Phase 2 randomized, open-label, active-controlled trial in the U.S. to investigate the safety, tolerability, and efficacy of once-weekly TransCon hGH (lonapegsomatropin; approved for pediatric growth hormone deficiency) compared to daily somatropin in prepubertal children with Turner syndrome.
New InsiGHTS randomized and dosed 49 children with Turner syndrome aged 1 to 10 years old into one of four treatment groups 1:1:1:1 – one of three starting doses of TransCon hGH (0.24, 0.30, or 0.36 mg/kg/week) or an active comparator of daily somatropin with a starting dose of 0.35 mg/kg/week. Doses were individualized based on IGF-1.
<ul>
<li>On the primary endpoint of annualized height velocity and secondary endpoint of change from baseline in height SDS, children treated with TransCon hGH demonstrated improved growth similar to daily somatropin at Week 26, independent of starting dose.
<ul>
<li>In the trial, TransCon hGH was generally safe and well tolerated, with no discontinuations related to study drug and with comparable safety and tolerability to daily somatropin.</li>
</ul>
</li>
</ul>

Ascendis Pharma Presents New InsiGHTS Trial Of TransCon hGH In Turner Syndrome Achieved Primary Objective At Week 26; Results For All Three TransCon hGH Starting Dose Cohorts, In First Clinical Trial Of An Indication Outside Of Growth Hormone Deficiency, Showed A Safety And Tolerability Profile Comparable To Daily Somatropin

Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) today announced that the U.S. Food &amp; Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) in adult growth hormone deficiency (GHD) for TransCon hGH (lonapegsomatropin-tcgd; marketed as SKYTROFA&#xAE; for pediatric GHD). The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of July 27, 2025.

Ascendis Pharma Announces FDA Accepts Co's Supplemental Biologics License Application For TransCon hGH For The Treatment Of Adults With Growth Hormone Deficiency

Ascendis Pharma's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NYSE">ASND</a>) short percent of float has risen 4.86% since its last report. The company recently reported that it has 3.57 million shares sold short, which is 8.42% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.6 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ascendis Pharma Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733242521_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ascendis Pharma has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ascendis Pharma's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ascendis Pharma's peer group average for short interest as a percentage of float is 11.40%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Ascendis Pharma's Recent Short Interest

TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Buy and lowers the price target from $160 to $153.

TD Cowen Maintains Buy on Ascendis Pharma, Lowers Price Target to $153

Wedbush analyst Andreas Argyrides reiterates Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Outperform and maintains $181 price target.

Reiteration

Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $181 Price Target

WIIM

Acendis Pharma shares are trading higher after Stifel maintained a Buy rating on the stock and raised its price target from $200 to $207.

Oppenheimer analyst Leland Gershell maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Outperform and lowers the price target from $190 to $180.

Oppenheimer Maintains Outperform on Ascendis Pharma, Lowers Price Target to $180

Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Overweight and maintains $170 price target.

Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $170 Price Target

Stifel analyst Alex Thompson maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Buy and raises the price target from $200 to $207.

Stifel Maintains Buy on Ascendis Pharma, Raises Price Target to $207

Guidance

Ascendis Sees FY24 Operating Expenses ~€600M

Ascendis Pharma shares are trading lower. The company reported Q3 financial results.

Earnings

Ascendis Q3 2024 Revenue $€57.8M Vs €48M Prior

Ascendis Pharma's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NYSE">ASND</a>) short percent of float has risen 5.52% since its last report. The company recently reported that it has 3.41 million shares sold short, which is 8.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 11.21 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ascendis Pharma Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731604512_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ascendis Pharma has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ascendis Pharma's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ascendis Pharma's peer group average for short interest as a percentage of float is 11.13%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(ASND) - Analyzing Ascendis Pharma's Short Interest

AFMD

AGAE

AIRI

AKYA

AMAT

AQMS

AREC

ASTS

AZUL

BENF

BILI

BIOR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BKTI

BKYI

BLUE

BNAI

BNZI

BRAG

BTAI

CASI

CELC

CINT

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNVS

CRIS

CWCO

DARE

DBGI

DESP

DFLI

DLPN

DMRC

DNMR

DPRO

DTST

EAST

EFXT

ELUT

EWCZ

FLNT

FTLF

GAMB

GAME

GCTS

GDEV

GLOB

HYLN

IMCC

INKT

INTR

ITRM

IVVD

IZEA

LCTX

LIQT

LOCL

LUNR

MITQ

MOVE

MSGM

MUFG

NICE

NOMD

NTES

OCFT

OCUL

OKLO

ONEW

ORGN

PDSB

PHGE

POCI

POST

Earnings Scheduled For November 14, 2024

An update from Ascendis Pharma ( ($ASND) ) is now available. Ascendis Pharma has announced updates to its Articles of Association, detailing author...

Ascendis Pharma Updates Articles for Financial Flexibility

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pharvaris (PHVS – Research Report), Ascendis Pharma (ASND – Resea...

Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Ascendis Pharma (ASND) and BioNTech SE (BNTX)

In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Ascendis Pharma (ASND – Research Report), w...

Bank of America Securities Sticks to Their Buy Rating for Ascendis Pharma (ASND)

UBS analyst Eliana Merle initiated coverage of Ascendis Pharma (ASND) with a Buy rating and $196 price target UBS thinks the next 1-3 years could b...

Ascendis Pharma initiated with a Buy at UBS

Analyst Derek Archila of Wells Fargo reiterated a Buy rating on Ascendis Pharma (ASND – Research Report), retaining the price target of $289.00. De...

Derek Archila's Buy Rating on Ascendis Pharma Backed by Promising Yorvipath Launch and Growth Potential

TD Cowen analyst Yaron Werber maintained a Buy rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $153.00. The comp...

TD Cowen Keeps Their Buy Rating on Ascendis Pharma (ASND)

BioMarin Pharmaceutical (BMRN) announced that the company has initiated a legal action against Ascendis Pharma (ASND) for infringement of European ...

BioMarin initiates legal action against Ascendis over patent infringement

J.P. Morgan analyst Jessica Fye has maintained their bullish stance on ASND stock, giving a Buy rating today. Jessica Fye's rating is based on seve...

Ascendis Pharma's Strategic Initiatives and Collaborations Drive Positive Growth Outlook and Buy Rating

The latest announcement is out from Ascendis Pharma ( ($ASND) ). On January 14, 2025, Ascendis Pharma's board of directors granted 82,103 warrants ...

Ascendis Pharma Grants Warrants to Employees

Artisan Mid Cap Fund Q4 2024 Commentary

AMZN

ANET

ARGX

BMRN

BNTX

CSGP

EXAS

GDDY

GOOG

GTLB

HOOD

HUBB

INSM

MNDY

MPWR

MRVL

MSFT

MTSI

ONTO

PHVS

PLTR

PSTG

SHOP

SPOT

TEAM

USFD

Press Releases

New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024

Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

Health Care

Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases

Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

Ascendis Pharma Reports Third Quarter 2024 Financial Results

FDA Accepts Ascendis Pharma's Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26

YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

Comments

Ascendis Pharma

空売り

Ascendis Pharma (NASDAQ:ASND) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル